Healthcare entity
Every one of those 1 sits in a single category, market-trends. XDEMVY is most often covered alongside ORIC Pharmaceuticals, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention XDEMVY, all published on February 23, 2026.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. XDEMVY is most often covered alongside ORIC Pharmaceuticals, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention XDEMVY, all published on February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering XDEMVY. Shared-story counts are live from our verified record — not editorial picks.
Tarsus Pharmaceuticals exceeded revenue expectations with $151.6 million in Q4 2025, driven by the commercial expansion of XDEMVY, while ORIC Pharmaceuticals demonstrated clinical-stage fiscal discipline with a narrowed quarterly loss. These results highlight the divergent financial profiles of commercial-stage specialty pharma versus pipeline-focused oncology developers.
Source: manilatimes.net · manilatimes.net
XDEMVY is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
